Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins.
ST 1059, the pharmacologically active metabolite of midodrine, is a powerful vasoconstrictor compound, acting by stimulation of alpha-receptors. It elicited 80% of noradrenaline-induced contraction of human veins.
D004087:Dihydroergotamine / Q000494:pharmacology*; D004983:Ethanolamines / Q000494:pharmacology*; D005039:Etilefrine / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008879:Midodrine / Q000031:analogs & derivatives / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology*; D010656:Phenylephrine / Q000031:analogs & derivatives*; D014662:Vasoconstrictor Agents; D014680:Veins / Q000187:drug effects
D004983:Ethanolamines; D014662:Vasoconstrictor Agents; D010656:Phenylephrine; C006146:ST 1059; D004087:Dihydroergotamine; D008879:Midodrine; D009638:Norepinephrine; D005039:Etilefrine